The clinical application of etanercept in Chinese patients with rheumatic diseases

References

• Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al., editors. Harrison's principles of internal medicine. 14th ed. vol. 2. New York: McGraw-Hill; 1998. p. 1880–8.
   Google Scholar
• Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072–82.
   PubMed Web of Science ®Google Scholar
• Chou CT, Pai L, Chang DM, Lee CF, Liang MH, Schumacher HR. Prevalence of rheumatic disease in Taiwan: a population-based study of urban, suburban, rural difference. J Ftheumatol (Canada) 1994;21:302–6.
   Google Scholar
• Van der Heijde DM, van Ftiel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sul-phasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036–8.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Long term pro-spective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Ftheumatol 1998;25:238–42.
   Google Scholar
• Spadaro A, Fticcieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treat-ment of psoriatic arthritis: a one-year prospective study. Clin Exp Ftheumatol 1995;13:589–93.
   Google Scholar
• Cuchacovich M, Soto L. Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis. Ann Rheum Dis 2002;61:942–3.
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39:2004–12.
   PubMed Web of Science ®Google Scholar
• Amor B, Dougados M, Khan MA. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995;21:117–28.
   Google Scholar
• Van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001;30(Suppl 2):7–16.
   PubMedGoogle Scholar
• Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and FtANKL pathways in tumor necrosis fac-tor-induced arthritis: effects on synovial inflammation, bone ero-sion, and cartilage destruction. Arthritis Rheum 2004;50: 277–90.
   Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. The ATTRACT Study Group. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrex-ate: a randomized phase III trial. Lancet 1999;354:1932–9.
   Google Scholar
• Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A study of etanercept, a recombi-nant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586–93.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594–602.
   PubMed Web of Science ®Google Scholar
• Brandt J, Haibel H, Sieper J, Redding J, Braun J: Infliximab treat-ment of severe ankylosing spondylitis: one-year follow-up. Arthri-tis Rheum 2001;44:2936–7.
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF therapy and other novel approaches. Arthritis Res 2002;4:307–21.
   PubMedGoogle Scholar
• Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a ran-domized controlled multicentre trial. Lancet 2002;359:1187–93.
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chi-meric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthri-tis Rheum 2002;46:755–65.
   PubMed Web of Science ®Google Scholar
• Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667–75.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385–90.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progres-sion. Arthritis Rheum 2004;50:2264–72.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in pa-tients with ankylosing spondylitis after 3 years of continuous treat-ment with infliximab. Arthritis Res Ther 2005;7:R439–44.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Ar-thritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnos-tic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55–78.
   PubMedGoogle Scholar
• Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis. J Ftheumatol 1998;25:1991–4.
   Google Scholar
• Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. the European Spondyloarthropathy Study Group. The European Spondyloarthropathy Study Group preliminary cri-teria for the classification of spondyloarthropathy. Arthritis Rheum 1991;34:1218–30.
   PubMed Web of Science ®Google Scholar
• Garrentt S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Ftheumatol 1994;21:2286–91.
   Google Scholar
• Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hear J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Ftheumatol 1994;21:2281–5.
   Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238–44.
   PubMedGoogle Scholar
• Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50: 859–66.
   Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
   Google Scholar
• Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. Etanercept added to back-ground methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum 2003;48:1493–9.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Arhtirtis Rheum 2002;46: 1445–50.
   Google Scholar
• Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, De Vries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis. Arthritis Rheum 2004;50: 353–63.
   Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewe R, Klareskog L, Rodriguez-Valverde V, Settas L, Pedersen R, et al. Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. Arthritis Rheum 2005;52:49–60.
   PubMed Web of Science ®Google Scholar
• Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid ar-thritis. Ann Rheum Dis 2006;65:35–9.
   PubMed Web of Science ®Google Scholar
• Khan MA, Van der Linden SM. Ankylosing spondylitis and other spondyloarthropathies. Rheum Dis Clin North Am 1990;16:551–79.
   PubMed Web of Science ®Google Scholar
• Khan MA. Prevalence of HLA-B27 in world population. In: Lopez-Larrea C, editor. HLA-B27 in the development of spondyloarthropathies. Austin, TX: Landes; 1997. p. 95–112.
   Google Scholar
• Feltkamp TEW, Mardjuadi A, Huang F, Chou CT. Spondy-loarthropathies in eastern Asia. Curr Opin Ftheumatol 2001;13: 285–90.
   PubMed Web of Science ®Google Scholar
• Chou CT, Cherng JM, Hsu CM, Chen SJ. HLA-B27 and its sub-types in 4 Taiwanese Aborigine tribes: a comparison to Han Chinese patients with ankylosing spondylitis. J Ftheumatol 2003;30: 321–5.
   Google Scholar
• Brandt J, Haibel H, Comely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346–52.
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349–56.
   Google Scholar
• Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224–33.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229–34.
   PubMed Web of Science ®Google Scholar
• Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Ftheumatology 2005;44:342–8.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Antoni CE. Psoriatic arthritis treatment: biological re-sponse modifiers. Ann Rheum Dis 2005;64 (Suppl
   Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: re-sults from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227–36.
   PubMed Web of Science ®Google Scholar
• van Dullemen HM, van Deventer SJ, Hommes DW, Bfil HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti- tumor necrosis factor chimeric monoclonal antibody (cA2). Gas-troenterology 1995;109:129–35.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119–33.
   PubMed Web of Science ®Google Scholar
• Stokes DG, Kremer JM. Potential of tumor necrosis factor neutral-ization strategies in rheumatologic disorders other than rheuma-toid arthritis. Semin Arthritis Rheum 33:1–18.
   Google Scholar
• Travis SPL, Czajkowski M, McGovern DPB, Watson RGP, Bell AL. Treatment of intestinal Behget's syndrome with chimeric tu-mour necrosis factor alpha antibody. Gut 2001;49:725–8.
   Google Scholar
• Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149–54.
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Ellman MH, Curran JJ, Utset TO, Park C. TNF-inhibition as novel treatment for refractory sarcoidosis. Arthritis Rheum 2005;53:788–91.
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Gangji V, Appelboom T. Effects of TNF blockade with infliximab in patients with primary Sjogren's syn-drome: an open pilot study (abstract). Presented at: European League Against Rheumatism (EULAR)/European Congress of Ftheumatology; Prague, Czech Republic, June 13–16, 2001. Ab-stract 0P0066.
   Google Scholar
• Kayser M, Unger L, NuBlein H. Treatment of rheumatoid vasculi-tis with infliximab (abstract). Ann Rheum Dis 2001;60:FRI0047.
   Google Scholar
• Kraetsch HG, Antoni C, Dechant C, Kalden JR, Manger B. Treat-ment of six patients with adult onset of Still's disease with infliximab (abstract). Presented at: European League Against Rheumatism (EULAR)/European Congress of Ftheumatology; Prague, Czech Republic, June 13–16,2001. Abstract 0229.
   Google Scholar
• Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252–7.
   PubMed Web of Science ®Google Scholar
• Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Safety 2004;27:307–24.
   Google Scholar
• Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Ftheumatol 2001;28:1238–44.
   Google Scholar
• Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013–22.
   Google Scholar
• Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance re-port. Arthritis Rheum 2003;48:2122–7.
   Google Scholar
• Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62: 829–34.
   Google Scholar
• Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lympho-mas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691–6.
   Google Scholar
• Kinlen U. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44–9.
   PubMed Web of Science ®Google Scholar
• Geborek P, Bladstrom A, Turesson C, Guile A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005;64:699–703.
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma develop-ment: twenty-six cases reported to the Food and Drug Administra-tion. Arthritis Rheum 2002;46:3151–8.
   Google Scholar
• Franklin JP, Symmons DP, Silman AJ. Risk of lymphoma in pa-tients with RA treated with anti-TNFalpha agents. Ann Rheum Dis 2005;64:657–8.
   Google Scholar
• Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807–11.
   Google Scholar